LHCCX Mutual Fund

NAV$22.45

Fund Essentials - as of Apr 30, 2026

Net Assets
-
Expense Ratio
1.78%
Dividend Yield (Current)
-
Holdings
64
Inception Date
Jul 31, 2019
Fund Family
Lord Abbett Family of Funds
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO
Dividend Frequency
Annually

Performance

YTD+4.19%
1 Year+26.33%
3 Year+8.30%
5 Year+4.86%

Asset Allocation

Stocks: 96.38%
Cash: 1.69%
Other: 1.93%

Price Chart (6M)

Loading chart data...

Top Holdings

View All →
TickerNameWeight
LLYEli Lilly And Company8.89%
AZN:LNAstrazeneca Plc Adr4.73%
GILDGilead Sciences Inc4.25%
JNJJOHNSON AND JOHNSON3.19%
NKTRNektar Therapeutics3.17%
Top 10 Concentration: 37.55%Report Date: Apr 30, 2026
Download all 64 holdings for LHCCX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Frequency
Annually
Latest Distribution
$1.47
-

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This Mutual Fund
PRO
Peer Avg
PRO
See how LHCCX ranks against its peers
Category rank, peer-average returns and outperformance, updated daily.
$49$29/mo
Claim the $29 launch price
First 500 subscribers, then $49/mo. Cancel anytime. From MarketXLS, trusted since 2014.

LHCCX Mutual Fund Overview

LHCCX Mutual Fund (Lord Abbett Health Care Fund) is managed by Lord Abbett Family of Funds. LHCCX expense ratio is 1.78%, holding 64 positions across sectors including Health Care, Unknown, Other. Inception date: 2019-07-31.

LHCCX performance shows a YTD return of 4.19%. The 1-year return is 26.33% and the 5-year return is 4.86%.

LHCCX top holdings include Eli Lilly And Company (8.9%), Astrazeneca Plc Adr (4.7%), Gilead Sciences Inc (4.3%), JOHNSON AND JOHNSON (3.2%), Nektar Therapeutics (3.2%). View all LHCCX holdings, sector breakdown, or dividend history.

LHCCX can be compared against other funds using the overlap calculator or side-by-side comparison tool. LHCCX alternatives are available via the screener, along with tax-loss harvesting opportunities.